Immix Biopharma, Inc. Common Stock (IMMX)
Score for how it compares with the broader market is near the top of its range; business numbers score is on the low side.
IMMX scores higher than 71% of the 1,101 tickers we compare it with (Health Care).
As of 9 October 2026, Immix Biopharma, Inc. Common Stock (IMMX) scores 52 out of 100 on the Market Census six-factor composite, which puts it at the Average score level. The score is made from six named factors: price trend, strength vs the market, company finances, insider trades, market mood and recent momentum. It records what they read on 9 October 2026, and it is not investment advice.
Updated · scores usually change about once a day
Key statistics
Market fields as reported. An em-dash means we hold no value for this ticker — most of the universe has no daily price or volume read.
- Relative volume
- 0.69× 30-day average
- 52-week range
- 2.31 – 15.10
- Market cap
- $894.24M
- Earnings date
- 5 Nov 2026
- Volume
- 1,109,043
- Avg. volume (30d)
- 1,609,385
- Open
- 9.29
- Previous close
- 9.29
- Day's range (regular session)
- 9.18 – 9.53
The last trade can be an extended-hours trade, so it can sit outside the regular-session range.
Shown without a peer ranking — we hold no percentile for these yet, so there is nothing here to locate them against.
- Beta
- 0.20
- P/E (TTM)
- —
- EPS (TTM)
- -0.87
Score breakdown · six named factors
Each bar is one part of the score, from 0 to 100. Read what the score means.
What the score says about IMMX right now
Immix Biopharma, Inc. Common Stock (IMMX) currently scores 52/100 on the Market Census six-factor composite, at the Average score level. IMMX is +1.83% on the day and -1.55% over five sessions as of the most recent tick. Average sits in the middle. The good and the bad in IMMX's data roughly balance out right now. IMMX's strongest factor is strength vs the market at 100/100 — a very strong read on how IMMX has done next to the wider market. It describes what has happened, not what happens next. The weakest factor is company finances at 0/100 — well below average company numbers. A low company-finances reading is the canonical "value trap" warning: technical setups on broken fundamentals don't tend to compound.
Generated from the six-factor breakdown above. Changes when the underlying scores do, usually about once a day. More on what the score means.
See IMMX in the scanner
This page is free to read with no account at all. Signing up takes an email and a password: a free account runs the scanner on the top 10 scored rows of any scan, keeps one saved screen, a 5-ticker watchlist, and opens 12 ticker detail pages a day. The card is what starts a 30-day Premium trial — $0 that day, then $19.99/month from day 30, cancel online any time before then — and that is what turns on every matching row instead of the first 10, alerts, the 200-ticker watchlist and recent insider buys (SEC Form 4).
Recent IMMX news
Latest headlines that name Immix Biopharma, one per story, sourced from Market Census’s news feed (Polygon/Massive + Finnhub).
- Immix Biopharma to Participate in the 45th Annual J.P. Morgan Healthcare ConferenceYahoo
- Immix Biopharma Reports 89% Complete Response in NXC-201 AL Amyloidosis StudyYahoo
- Immix Biopharma Announces Closing of $125 Million Underwritten Offering of Common StockYahoo
- Immix Biopharma, Inc. (IMMX) Shareholder/Analyst Call TranscriptSeekingAlpha
- Immix Biopharma Reports 89% Complete Response Rate in Phase 2 NXC-201 TrialYahoo
We hide 5 more that told readers to buy or sell, or gave a price target.
Saved snapshot; the news and prices on this page can be an hour old or more.
Similar setups in Health Care right now
Six health care tickers whose composite scores are closest to IMMX’s 52, all within 1 point.
Sorted by closeness to IMMX’s composite score within Health Care. Saved snapshot; can be an hour old or more. Run the full scanner →
Prices delayed about 15 minutes; scores usually change about once a day. Not investment advice — see risk disclosure.